Array The past three years have been some of the most eventful in memory for Taiwan’s life sciences industry. At this year’s Bio Taiwan exhibition, the annual conference that invites the international life sciences com-munity to the island, the excitement was palpable. Foreign companies turned out in record numbers to…
Array The CEO of ASLAN Pharmaceuticals discusses the fundamental changes that need to occur in the treatment of serious illnesses, the advantages of building a second branch in Taiwan, and the key differences between the industry in Taiwan and Singapore. ASLAN is busy setting up a subsidiary in Taiwan. What attracted…
Array Ask Indonesians about a bad experience in medical care and each will have a story to tell. The poor state of Indonesia’s healthcare system has turned ‘improving quality’ into the top priority of the government of Indonesia. Better quality of care has become especially important as the fourth most populated…
Array The latest details regarding Article 46, a key piece of legislation attached to the second-generation health insurance reform, were announced this week. What are the key points to take away from this announcement? In Taiwan, the government is attempting to limit the growth of annual spending on pharmaceuticals—an expenditure that…
Array In 2010, you began your last interview with us by mentioning two things: that because of the nature of this affiliate’s portfolio—with only 35% of revenues generated by pharma at the time—Hospira’s strategy in Taiwan was a bit different than it was elsewhere in the world. You also said that…
Array Ulf Wiinberg has been CEO of Lundbeck since June 2008. He was previously with Wyeth for 27 years. Ulf Wiinberg is a board member of EFPIA in Europe and of PhRMA in the United States and serves on the Industrial Policy Committee under the Confederation of Danish Industry (Dansk Industris…
Array An in-depth viewpoint on the current taxation situation for pharmaceutical companies operating in Belgium today, looking at incentive programs and relative positioning in Europe. Mr Eynatten, can you please provide our readers with an overview of the value added services that Deloitte offers to the life sciences industry in…
Array Donald Niesten and Omer Saka discuss the current dynamics of the healthcare and pharmaceutical sectors in Belgium, the challenges of entering the market and the issue of effective communication with stakeholders, as well as offering opinions on the merits of ‘clusterization’. Deloitte is certainly renowned for its strong network…
Array Smart Scale was recently certified and recognized for its international quality standards. What have been the main growth drivers? Our experience and deep knowledge of the pharmaceutical market has been re-warded by the ISO 9001:2008 certification which we managed to get when the com-pany was established. It shows that we…
Array After just six months in the country, Novartis Australia’s new Managing Director offers his perspectives on the Australian pharmaceutical market and healthcare system, his company’s commitment to R&D, and Australia’s competitiveness for clinical trials in the Asian context. You arrived in July 2012 after working in different positions for…
Array The managing director of Brussels Invest & Export discusses Belgium’s unique attractiveness when it comes to the life sciences, and which countries and companies are interested in investing in the pharmaceutical sector in the country and why. After its creation in 2003, Invest in Brussels joined forces with Brussels…
Array As a Taiwanese national and Country Head of Novartis Taiwan, what is your opinion on the current state of the pharmaceutical industry in Taiwan, and what are your hopes for the future? I am of the opinion that it is going to get worse before it gets better. The National…
See our Cookie Privacy Policy Here
